JCXH-211

N/A

Report date: 2026/03/26 20:00:17
First In Class

Base Information

Drug NameJCXH-211
Drug Alias Nameself-amplifying mRNA JCXH-211JCXH-211
ClassificationCell and gene therapy > Gene therapy > mRNA > self-amplifying mRNA (SAM)Cell and gene therapy > Gene therapy > mRNA
Mechanisms of ActionInterleukin-12 stimulants
TargetsInterleukin-12
Therapy Area/IndicationsSolid tumoursSkin NeoplasmsGlioma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesImmorna (Hangzhou) Biotechnology Co., Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesImmorna Biotherapeutics IncImmorna (Hangzhou) Biotechnology Co., Ltd
Inactive CompaniesDuke University
Active IndicationsSolid tumoursSkin NeoplasmsNeoplasms
Inactive IndicationsGlioma

Other Information

ATC CodeN/A
Related LinksN/A